We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-5.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.54B
AUM Growth
-$303M
Cap. Flow
-$71.8M
Cap. Flow %
-2.82%
Top 10 Hldgs %
38.38%
Holding
180
New
5
Increased
27
Reduced
36
Closed
3

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14M
2
ISRG icon
Intuitive Surgical
ISRG
+$11.4M
3
BSX icon
Boston Scientific
BSX
+$9.19M
4
AZN icon
AstraZeneca
AZN
+$8.8M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.52M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$19.5M
2
MCK icon
McKesson
MCK
+$14.5M
3
MDT icon
Medtronic
MDT
+$11M
4
LLY icon
Eli Lilly
LLY
+$10.6M
5
ILMN icon
Illumina
ILMN
+$7.92M

Sector Composition

Rank Sector Weight
1 Healthcare 95.42%
2 Real Estate 3.13%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
76
Ionis Pharmaceuticals
IONS
$8.6B
$6.5M 0.26%
175,680
– –
XNCR icon
77
Xencor
XNCR
$1.5B
$6.49M 0.25%
236,996
+124,323
+110% +$3.07M
ASND icon
78
Ascendis Pharma A/S
ASND
$16B
$6.3M 0.25%
67,794
– –
MPT
79
Medical Properties Trust
MPT
$2.77B
$6.29M 0.25%
411,743
– –
SNY icon
80
Sanofi
SNY
$103B
$6.18M 0.24%
123,454
– –
TVTX icon
81
Travere Therapeutics
TVTX
$5.2B
$6M 0.24%
247,678
– –
ALKS icon
82
Alkermes
ALKS
$8.22B
$5.66M 0.22%
190,122
– –
MRTX
83
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.62M 0.22%
83,784
– –
BPMC
84
DELISTED
Blueprint Medicines
BPMC
$5.61M 0.22%
111,118
+13,865
+14% +$812K
ARWR icon
85
Arrowhead Research
ARWR
$11.9B
$5.52M 0.22%
156,875
+22,063
+16% +$830K
A icon
86
Agilent Technologies
A
$39.1B
$5.13M 0.2%
43,191
-23,654
-35% -$2.91M
SNN icon
87
Smith & Nephew
SNN
$13.3B
$5.07M 0.2%
181,710
– –
ACHC icon
88
Acadia Healthcare
ACHC
$2.76B
$4.89M 0.19%
72,307
– –
CYTK icon
89
Cytokinetics
CYTK
$10.5B
$4.71M 0.19%
119,898
– –
ALGN icon
90
Align Technology
ALGN
$12.1B
$4.47M 0.18%
18,894
– –
RCM
91
DELISTED
R1 RCM Inc. Common Stock
RCM
$4.24M 0.17%
202,351
– –
VECT
92
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$4.08M 0.16%
756,502
– –
DOC icon
93
Healthpeak Properties
DOC
$15.1B
$3.9M 0.15%
150,392
– –
CRBU icon
94
Caribou Biosciences
CRBU
$145M
$3.8M 0.15%
699,377
– –
ARVN icon
95
Arvinas
ARVN
$518M
$3.62M 0.14%
85,997
– –
PHG icon
96
Philips
PHG
$25.7B
$3.55M 0.14%
192,454
-7,044
-4% -$152K
TEVA icon
97
Teva Pharmaceuticals
TEVA
$40.8B
$3.46M 0.14%
459,651
– –
STE icon
98
Steris
STE
$22.3B
$3.44M 0.14%
16,669
– –
CRSP icon
99
CRISPR Therapeutics
CRSP
$4.73B
$3.35M 0.13%
55,080
– –
NVAX icon
100
Novavax
NVAX
$1.2B
$3.28M 0.13%
63,800
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Tekla Capital Management held 180 positions worth $2.54B, down 11% from $2.85B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Trading was light in Q2 2022: portfolio turnover was 4.4%. Tekla Capital Management opened 5 new positions and exited 3, leaving the 180-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q2 2022 buy was Lantheus: 127,092 shares worth $8.39M.
  • Tekla Capital Management added most to Vertex Pharmaceuticals in Q2 2022, an estimated $14M increase.
  • Tekla Capital Management's biggest Q2 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $19.5M.
  • Tekla Capital Management fully exited Revvity in Q2 2022, selling an estimated $5.83M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.54B portfolio in Q2 2022.
  • Tekla Capital Management opened 5 new positions and closed 3 in Q2 2022.
  • Tekla Capital Management's portfolio value fell 11% quarter-over-quarter to $2.54B.

Based on Tekla Capital Management's 13F filing for Q2 2022, filed 29 Jul 2022.